1. Home
  2. CFND vs NRXP Comparison

CFND vs NRXP Comparison

Compare CFND & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

N/A

Current Price

$3.80

Market Cap

27.4M

Sector

N/A

ML Signal

N/A

Logo NRX Pharmaceuticals Inc.

NRXP

NRX Pharmaceuticals Inc.

HOLD

Current Price

$1.88

Market Cap

54.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFND
NRXP
Founded
N/A
2015
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.4M
54.2M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
CFND
NRXP
Price
$3.80
$1.88
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$31.50
AVG Volume (30 Days)
22.7K
497.3K
Earning Date
N/A
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$847.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.68
$1.58
52 Week High
$9.67
$3.84

Technical Indicators

Market Signals
Indicator
CFND
NRXP
Relative Strength Index (RSI) 43.21 49.93
Support Level $3.75 $1.65
Resistance Level $4.08 $1.99
Average True Range (ATR) 0.18 0.09
MACD 0.03 0.02
Stochastic Oscillator 40.28 63.49

Price Performance

Historical Comparison
CFND
NRXP

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About NRXP NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Share on Social Networks: